組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6) :開發中產品分析
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 126.96.36.199) - Drugs In Development, 2021
|出版商||Global Markets Direct||商品編碼||363572|
|出版日期||內容資訊||英文 154 Pages
|組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6) :開發中產品分析 Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 188.8.131.52) - Drugs In Development, 2021|
|出版日期: 2021年08月31日||內容資訊: 英文 154 Pages||
本報告提供組蛋白去乙醯酵素6 (組蛋白去乙醯梅6 - HDAC6)的開發情形相關的資訊，各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析，開發治療藥的企業概要，最新消息和新聞稿等資訊，為您概述為以下內容。
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 184.108.40.206) - Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 220.127.116.11) pipeline Target constitutes close to 51 molecules. Out of which approximately 42 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 27 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology, Toxicology, Infectious Disease, Undisclosed, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Multiple Myeloma (Kahler Disease), Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Breast Cancer, Charcot-Marie-Tooth Disease Type II, Solid Tumor, Charcot-Marie-Tooth Disease, Chemotherapy Induced Peripheral Neuropathy, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Multiple Sclerosis, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Triple-Negative Breast Cancer (TNBC), Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Mantle Cell Lymphoma, Ovarian Cancer, Pancreatic Cancer, Rheumatoid Arthritis, Squamous Cell Carcinoma, Systemic Lupus Erythematosus, Unspecified, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Anal Cancer, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), CNS Lymphoma, Coronavirus Disease 2019 (COVID-19) Pneumonia, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Diabetic Neuropathic Pain, Diabetic Peripheral Neuropathy, Diastolic Heart Failure, Dilated Cardiomyopathy, Distal Symmetric Polyneuropathy, Fibrosis, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus (HPV) Associated Cancer, Huntington Disease, Idiopathic Pulmonary Fibrosis, Liver Cancer, Lung Adenocarcinoma, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Mycosis Fungoides, Myelodysplastic Syndrome, Myeloproliferative Disorders, Neuroblastoma, Neurology, Neuropathic Pain (Neuralgia), Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Polycystic Kidney Disease, Prostate Cancer, Rectal Cancer, Recurrent Medulloblastoma, Rett Syndrome, Sepsis, Small-Cell Lung Cancer, Systemic Sclerosis (Scleroderma), Tauopathies, Ulcerative Colitis, Unspecified B-Cell Lymphomas and Vulvar Cancer.
The latest report Histone Deacetylase 6 - Drugs In Development, 2021, outlays comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 18.104.22.168) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 22.214.171.124) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.